Protective effect of remote ischemic pre-conditioning on patients undergoing cardiac bypass valve replacement surgery: A randomized controlled trial

XIULING JIN, LIANGRONG WANG, LILING LI and XIYUE ZHAO

Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China

Received February 5, 2018; Accepted December 28, 2018

DOI: 10.3892/etm.2019.7192

Abstract. Remote ischemic pre-conditioning (RIPC) may have a protective effect on myocardial injury associated with cardiac bypass surgery (CPB). The objective of the present study was to investigate the effect of RIPC on ischemia/reperfusion (I/R) injury and to assess the underlying mechanisms. A total of 241 patients who underwent valve replacement were randomly assigned to receive either RIPC (n=121) or control group (n=120). The primary endpoint was peri-operative myocardial injury (PMI), which was determined by serum Highly sensitive cardiac troponin T (hsTnT). The secondary endpoint was the blood gas indexes, acute lung injury and length of intensive care unit stay, length of hospital stay and major adverse cardiac vascular events. The results indicated that in comparison with control group, RIPC treatment reduced the levels of hsTnT at 6 and 24 h post-CPB (P<0.001), as well as the alveolar-arterial oxygen pressure difference and respiratory index after CPB. Furthermore, RIPC reduced the incidence of acute lung injury by 15.3% (54.1% in the control group vs. 41.3% in the RIPC group, P=0.053). It was indicated that RIPC provided myocardial and pulmonary protection during CPB. In addition, the length of the intensive care unit and hospital stay was reduced by RIPC. Mechanistic investigation revealed a reduced content of soluble intercellular adhesion molecule-1, endothelin-1 and malondialdehyde, as well as elevated levels of nitric oxide in the RIPC group compared with those in the control group. This indicated that RIPC protected against I/R injury associated with CPB through reducing the inflammatory response and oxidative damage, as well as improving pulmonary vascular tension. In conclusion, RIPC reduced myocardial and pulmonary injury associated with CPB. This protective effect may be associated with the inhibition of the inflammatory response and oxidative injury. The present study proved the efficiency of this approach in reducing ischemia/reperfusion injury associated with cardiac surgery. Clinical trial registry no. ChiCTR1800015393.

Introduction

Heart surgery with cardiopulmonary bypass (CPB) is a primary treatment strategy for patients with coronary artery disease. As blood circulation in the myocardium is avoided during heart surgery, ischaemia-reperfusion (I/R) injury may occur during cardiopulmonary arrest.

A prominent characteristic of ischaemic injury is a reduced vascular endothelium-dependent vasodilation. Nitric oxide (NO) (1) and endothelin-1 (ET-1) (2) are two critical endothelium-derived factors. NO has a fundamental biological role in protecting organs (such as the heart) against I/R injury (3-5). In particular, the protective role of NO in the heart (6) and kidney (7) have been proven. Furthermore, the generation of ET-1 is aggravated under ischaemic conditions (8). In addition, substantial evidence has indicated that I/R injury associated with CPB is closely linked with the systemic inflammatory response (SIRS) (9,10). The important roles of inflammation have also been reported in the pathogenesis of brain ischemia (11-13). Various inflammatory factors, including soluble intercellular adhesion molecule-1 (sICAM-1) and ET-1 (14), participate in inflammatory processes. Furthermore, oxidative stress contributes to the pathogenesis of I/R injury (15).

It has been proved that the production of oxygen radicals is directly associated with major tissue and organ damage (16). Furthermore, toxic oxygen metabolites, including the lipid peroxidation product malondialdehyde (MDA) (17), exert damaging effects on multiple pathophysiological processes.

Peri-operative myocardial injury (PMI) is a type of injury that typically occurs in patients who received valve surgery (18). Furthermore, due to the effects of anesthetic drugs and mechanical ventilation, pulmonary compliance of the patients gradually decreases with the time of ventilation progressing. During CPB, the pulmonary function is impaired by the continuous low perfusion of the lungs and pre-flush-mediated blood dilution (19).
Such lung I/R injury may affect the functions of other organs in the patients after the operation.

Based on these investigations, it is necessary to develop effective therapeutic interventions so as to protect against tissue injury (20). Remote ischaemic pre-conditioning (RIPC) has been recognized as a low-cost, non-invasive intervention method by applying brief ischaemia and reperfusion on an arm or a leg. RIPC exerts protective effects on remote tissue or organs against lethal acute I/R injury (21-24). RIPC may be achieved by performing a standard blood-pressure cuff (25). While the effect is not obvious under certain conditions (25-27), application of RIPC has produced beneficial outcomes in patients who received open-heart surgery (27-30) or coronary intervention (31). In addition, the protective effect of RIPC on the kidney has been previously demonstrated (32). However, whether RIPC has the capacity to prevent myocardial and lung I/R injury has remained to be fully demonstrated.

The overall objective of the present study was to investigate the protective effect of RIPC on myocardial and lung I/R injury. Furthermore, the present study aimed to elucidate the possible underlying mechanisms.

Materials and methods

Study design. The present randomized controlled trial was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China). Written informed consent was received from each patient included in the study. Patients who received valve surgery at the First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China) between July 2012 and July 2015 were recruited. The inclusion criteria were mitral valve disease, aortic valve disease or combined valvular disease and patients with stable hemodynamic blood. The exclusion criteria were, infection, chronic lung disease, medications that may interfere with stable hemodynamic blood. The exclusion criteria were, hypertension, congenital heart valve disease, preoperative hospital admission and peripheral arterial disease affecting the limbs, complicated coronary heart disease, complicated hypertension, congenital heart valve disease, preoperative stroke, simultaneous radiofrequency ablation of atrial fibrillation and reoperate. The recruited patients were randomly divided into two groups. In the grouping process, the information regarding treatment allocation was delivered by a nurse who was not involved in the study. The investigators who analyzed the data were blinded to the treatment allocation.

Intervention. In the RIPC and control groups, surgery was initiated after anaesthesia and completed prior to sternotomy. An intense multi-limb method was performed consisting of two 5-min cycles of simultaneous upper arm and thigh cuff inflation and deflation (simultaneous inflation to 200 mmHg, left inflation for 5 min and then deflation to 0 mmHg and left deflated for 5 min) (32). In the control group, patients were not subjected to any preconditioning. The intervention was performed without any arterial line on the arm, and the blood-pressure cuffs on the arms were bound up.

Anesthesia and surgical protocol. Patients were intramuscularly injected with 0.3 mg/kg scopolamine and 0.2 mg/kg morphine at 0.5 h prior to the surgery. All patients were routinely monitored via electrocardiogram, non-invasive blood pressure, invasive radial arterial pressure, heart rate and respiration using a multifunctional monitor. Anaesthesia was induced with midazolam valium (0.1 mg/kg), sufentanil (0.5 µg/kg), vecuronium bromide (0.15 mg/kg) and propofol (2.0 mg/kg). Mechanical ventilation was maintained by a Datex-Ohmeda Aestiva/5 anaesthesia machine (GE Healthcare, Little Chalfont, UK) with the tidal volume set at 8-10 ml/kg and the suction/call ratio set at 1:2. The normal-end tidal carbon dioxide pressure was maintained at 26-32 mmHg by setting the respiratory frequency at 11-13 breaths/min. Myocardium was protected by perfusion of cold blood cardioplegia. The concentration of K⁺ was 23-24 mmol/l. Surgery was performed with a median sternal incision. The distal ascending aorta was inserted into the arterial infusion tube. The superior and inferior venas cava were inserted into the vena cava drainage tube. The aortic valve was replaced with the atrial cavity tube, and the right superior pulmonary vein was placed in the left cardiac drainage to establish extracorporeal circulation. Mitral valve replacement was performed through the right atrial septal incision, with continuous or intermittent sutures. Aortic valve replacement was performed through the aortic root incision with intermittent suture. If the tricuspid valve has a lesion, it may be shaped or replaced at the same time. A standard CPB was performed using the Stöckert III perfusion system (Stöckert GmbH, Munich, Germany), which was followed by valve replacement. The surgery was completed and protamine was employed to achieve heparin reversal (protamine/heparin, 1:1.2:1).

Primary and secondary endpoints. The primary endpoint of the present study was PMI. Highly sensitive cardiac troponin T (hsTnT) was detected as a marker for PMI. Furthermore, the present study had two secondary endpoints, one of which were the blood gas indexes, acute lung injury (ALI) and length of intensive care unit (ICU) stay, while the other one was length of hospital stay and major adverse cardiovascular events at 90 days (death, myocardial infarction or stroke).

Detection of serum markers. Blood samples were collected pre-operatively (T1) and at 5 min (T2), 2 h (T3), 6 h (T4) and 24 h (T5) after CPB. hsTnT was quantitated by one-step enzyme immunoassay technology (Elecsys 2010; Roche Diagnostics, Basel, Switzerland) as described previously (33). hsTnT levels of ≥14 ng/l were considered to indicate severe myocardial injury. The content of sICAM-1 was determined by ELISA (sICAM-1; cat. no. 48T967; Xitang Biotechnology, Shanghai, China) and the optical density value was recorded by a microplate reader (Multiskan Spectrum; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Furthermore, the level of ET-1 was detected using an immunoassay (ET-1; cat. no. 990826; Beijing Institute of East Asian Institute of Immunology, Beijing, China) according to the manufacturer's protocol. The contents of MDA and NO were measured using spectrophotometrical assays (MDA, cat. no. A003-1; NO, cat. no. A013-2; Nanjing Jiancheng Bioengineering Institute, Jiangsu, China).

Blood gas analysis and ALI estimation. Alveolar-arterial oxygen pressure difference [P(A-aDO₂)] and respiratory index (RI) were considered as blood gas indexes. The partial oxygen...
pressure (PaO$_2$), partial CO$_2$ pressure (PaCO$_2$) and fraction of inspired oxygen (FiO$_2$) were recorded using an i-STAT (Abbott, Princeton, NJ, USA) and used to calculate the P(A-aDO$_2$) and RI using the following formulas: P(A-aDO$_2$)=$(\text{Patm}-\text{PH}_2\text{O})$ x FiO$_2$-PaCO$_2$/R-PaO$_2$, and RI=Pa(A-aDO$_2$)/PaO$_2$, where Patm is the atmospheric pressure of 760 mmHg and PH$_2$O is the water vapor pressure of 47 mmHg. ALI was estimated according to the diagnostic criteria of American-European Consensus Conference on the acute respiratory distress syndrome/ALI (34): i) PaO$_2$/FiO$_2$ <300 mmHg; ii) no atelectasis, no pleural effusion and no pneumothorax; and iii) no congestive heart failure.

Statistical analysis and sample size estimation. Values are expressed as the mean ± standard deviation. Comparison between groups was performed using Student's t-test or Wilcoxon Mann Whitney test for continuous variables that were normally distributed or not, respectively. The Chi-squared and Fisher's Exact test were used for discontinuous variables. Two-way analysis of variance followed by Bonferroni's post-hoc test was used to analyze differences among groups for serum markers collected at different time-points. Assuming a statistical power of 90% and a type I error rate of 5%, this required a sample size of 120 subjects (which accommodated withdrawal or missing data-points). SPSS 20.0 (IBM Corp., Armonk, NY, USA) and GrahPad Prism 5 (GraphPad Inc., La Jolla, CA, USA) were used to analyze the data. P<0.05 was considered to indicate a statistically significant difference.

Results

Patients. A total of 280 patients were assessed for recruitment eligibility, and 241 patients were finally enrolled and assigned to the RIPC (n=121) or control (n=120) group (Fig. 1). With regard to the basic characteristics, no significant difference was identified between the two groups (Table I). Furthermore, no adverse events (death, myocardial infarction or stroke) associated with the RIPC protocol were observed.

Effect of RIPC on myocardial injury and lung injury. The baseline hsTnT levels in the two groups were similar and no significant difference was observed. It was identified that the levels of hsTnT in the RIPC group were reduced at 6 and 24 h post-CPB as compared with those in the control group (P<0.05, Fig. 2). P(A-aDO$_2$) and RI are direct indicators of pulmonary ventilation and oxygenation function (35), and these two parameters exhibited an increasing trend at first, followed by a gradual decline gradual after CPB was performed in each of the two groups [the decline occurred: P(A-aDO$_2$), T4; RI, RIPC, T5, Control, T4]. After CPB, the P(A-aDO$_2$) was identified to be significantly lower in the RIPC group compared with that in the control group at the same time-points (Table II, Fig. 3A). The RI in the control group was significantly higher than that in the RIPC group at 2, 6 and 24 h after CPB (Table II, Fig. 3B). Furthermore, RIPC achieved a reduction in the incidence of ALI from 54.1 to 41.3% (P=0.053 vs. control group, Table II).

Effect of RIPC on other endpoints. The length of ICU stay was shortened by the RIPC treatment (P<0.05, Table II). The duration of the hospital stay in the RIPC group was also short, but not significant compared with that in the control group (P=0.24, Table II). In addition, no significant difference in the occurrence rate of death, myocardial infarction and stroke was identified between the RIPC and the control group (Table II).

Discussion

In the present prospective study, it was demonstrated that RIPC decreased the PMI of patients receiving valve replacement. Certain studies have proved that RIPC has beneficial effects in terms of reducing PMI (27,28,30), which has also been demonstrated in a recent meta-analysis (36). However, no significant cardioprotective effect of RIPC was indicated in...
JIN et al: PROTECTIVE EFFECT OF RIPC

257 cases underwent randomization

| 128 were allocated to RIPC group |
| 121 received assigned intervention |
| 7 did not receive assigned intervention |

| 129 were allocated to control group |
| 120 received assigned intervention |
| 9 did not receive assigned intervention |

121 were included in the intention-to-treat primary end-point analysis. None was lost to follow-up.

120 were included in the intention-to-treat primary end-point analysis. None was lost to follow-up.

121 were analyzed

120 were analyzed

---

Certain other previous studies (25,37). Notably, RIPC may not reduce hsTnT levels, renal injury or ICU-support requirements in high-risk cardiac surgery in patients receiving generous doses of opioids as well as propofol and volatile anaesthesia, which differed from the effective trials. The intense technique used in the present study was more rapid (requires only 20 min) than the standard single-limb RIPC protocol (requires 40 min). Thus, it was possible to perform multi-limb RIPC prior to sternotomy. Furthermore, the different relative timing of RIPC and the concomitant therapy in patients undergoing cardiac surgery may contribute to the conflicting results among studies (25,26,32).

Another conclusion of the present study was that RIPC treatment elicited protective effects on the lung. Pulmonary artery blood flow was completely disrupted under CPB, and lung I/R injury was induced during this process. Post-operative pulmonary dysfunction has been identified as one of the most important factors contributing to the cardiac surgery-associated mortality (38). Pulmonary oxygenation, an important indicator for evaluating lung function when lung injury occurs, may be directly reflected by the \( P(A-aDO_2) \) and RI (35). In the present study, RIPC was indicated to achieve a reduction of the \( P(A-aDO_2) \) and RI after CPB compared with that in the control group, suggesting an improvement in the oxygenation of the patients in RIPC group. In addition, ALI may be triggered by valve replacement surgery (39). Although no significant difference was noted in comparison with the control group, the incidence of ALI was slightly reduced in the RIPC group. Furthermore, the length of ICU and hospital stays following cardiac surgery was shortened by RIPC. This result was in line with a previous study (32). In the present study, RIPC treatment also reduced kidney injury in patients after cardiac surgery (32,40). All of these results proved the protective effect of RIPC on various organs.
Although the mechanisms underlying the protective effect of RIPC remain to be fully elucidated, a mechanistic model for the interaction between the pre-conditioned limb and the remote organ has been proposed (22, 41). Previous studies have demonstrated that ischemic pre-conditioning suppressed the inflammatory response and improved the anti-oxidant capacity of tissues (42, 43). In addition, the lung is highly susceptible to oxidative stress due to its large surface area (44). The effect of RIPC on the inflammation status and oxidation was then investigated in the present study. The results indicated that the release of sICAM-1 and ET-1 was mitigated and the content of lipid peroxidation product MDA after CPB was decreased by RIPC. These results indicated that RIPC produced a protective effect through inhibiting SIRS and oxidative stress in lung tissues. Furthermore, the decreased ET-1 in the RIPC group also suggested that the strength of myocardial constriction was closely associated with blood vessels. NO is a vasoactive factor and has relaxation effects, which were contrary to ET-1 (45). Consistently, it increased production of NO in the RIPC group, pointing to the improvement of pulmonary vascular tension. Taken together, it was concluded that RIPC elicits a protective effect by reducing the inflammatory status and improving the anti-oxidant capacity.

A limitation of the present study was that the effect of RIPC was not assessed in children, as all subjects were adult patients. The small-scale cohort and single-center design of the present study were further limitations of this study. Undoubtedly, the effect of RIPC should be explored on a larger scale and subjects should be recruited from multiple medical centers.

In conclusion, the present study demonstrated that RIPC alleviated PMI and lung I/R injury and may improve clinical outcomes, including shortened ICU stay, decreased hsTnT level at 6 and 24 h post-surgery, decreased P(A-aDO\(_2\)) level beginning from 5 min post-surgery and decreased RI level beginning from 2 h post-surgery, in adult patients undergoing valve replacement. The protective effect of RIPC may be

| Endpoint | Control group (n=120) | RIPC group (n=121) | Mean difference (95% CI) | P-value |
|----------|-----------------------|--------------------|--------------------------|---------|
| hsTnT (µg/l) |                        |                    |                          |         |
| T1       | 0.014±0.016           | 0.016±0.018        | -0.002 (-0.060 to 0.064) | >0.999  |
| T2       | 0.020±0.011           | 0.022±0.013        | -0.001 (-0.061 to 0.063) | >0.999  |
| T3       | 0.143±0.061           | 0.122±0.059        | -0.021 (-0.083 to 0.041) | >0.999  |
| T4       | 0.783±0.412           | 0.614±0.336        | -0.169 (-0.231 to -0.106) | <0.001  |
| T5       | 0.536±0.314           | 0.423±0.254        | -0.113 (-0.175 to -0.050) | <0.001  |
| P(A-aDO\(_2\)) (mmHg) |                     |                    |                          |         |
| T1       | 19.96±1.47            | 19.09±1.61         | -0.8600 (-10.14 to 8.424) | >0.999  |
| T2       | 152.16±23.80          | 89.98±28.70        | -62.18 (-71.46 to -52.90) | <0.001  |
| T3       | 182.70±47.74          | 142.3±33.17        | -40.32 (-49.60 to -31.04) | <0.001  |
| T4       | 137.94±31.15          | 121.6±31.54        | -16.29 (-25.57 to -7.006) | <0.001  |
| T5       | 82.83±26.60           | 56.02±18.89        | -26.81 (-36.09 to -17.53) | <0.001  |
| RI       | 0.255±0.14            | 0.258±0.08         | 0.003 (-0.079 to 0.085)  | >0.999  |
| T2       | 0.318±0.11            | 0.292±0.09         | -0.026 (-0.108 to 0.056) | >0.999  |
| T3       | 1.538±0.75            | 0.629±0.20         | -0.909 (-0.991 to -0.826) | <0.001  |
| T4       | 1.057±0.34            | 0.739±0.22         | -0.318 (-0.400 to -0.235) | <0.001  |
| T5       | 0.646±0.38            | 0.403±0.12         | -0.243 (-0.325 to -0.160) | <0.001  |
| ALI      | 65 (54.1)             | 50 (41.3)          | NA                       | 0.053a  |
| ICU stay (h) | 72.28±10.5         | 53.59±8.45        | NA                       | <0.001b |
| Hospital stay (days) | 17.56±3.64     | 16.98±4.01        | NA                       | 0.241c  |

Mean differences, 95% CIs of the differences and P-values in different times of hsTnT, P(A-aDO\(_2\)) and RI levels were analyzed by two-way analysis of variance. *P-value determined by chi-square test. **P-value determined by Student's t-test. ***P-value determined by Fisher's Exact test. Values are expressed as the mean ± standard deviation or n (%). Time-points: T1, prior to surgery; T2, 5 min post-surgery; T3, 2 h post-surgery; T4, 6 h post-surgery; T5, 24 h post-surgery. hsTnT, high-sensitive troponin-T; P(A-aDO\(_2\)), alveolar-arterial oxygen pressure difference; RI, respiratory index; ICU, intensive care unit; RIPC, remote ischaemic pre-conditioning; NA, not applicable; ALI, acute lung injury; CI, confidence interval.
associated with the reduction of inflammation and oxidative stress. However, large-scale and multi-center randomized controlled trials should be performed in order to confirm the precise effects of RIPC.

Acknowledgements

None.

Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors’ contributions

XL and LW made substantial contributions to the conception and design of the present study. LL and XZ were responsible for acquisition, analysis and interpretation of data. XJ and XZ were responsible for drafting the article and critically revising it for important intellectual content. All authors provided final approval of the version to be published.
Ethical approval and consent to participate

The present randomized controlled trial was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China). Written informed consent was provided by each of the patients included.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Ignarro L, Buga GM, Wood KS, Byrns RE and Chaudhuri G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84: 9265-9269, 1987.
2. Yamagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K and Masaki T: A novel potent vasodilator substance produced by vascular endothelial cells. Nature 332: 411-415, 1988.
3. Jalowy A, Schulz R and Heusch G: AT1 receptor blockade in experimental myocardial ischemia/reperfusion. J Am Soc Nephrol 10 (Suppl 11): S129-S136, 1999.
4. Kabola I, Han X, Opel DJ, Zhao M, Baliga R, Huang P, Fishman MC, Shannon RP, Michel T and Kelly RA: Increased susceptibility to development of triggered activity in myocytes from mice with targeted disruption of endothelial nitric oxide synthase. J Mol Cell Cardiol 32: 1239-1248, 2000.
5. Boll R: Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 33: 1897-1918, 2001.
6. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM and Cohen MV: Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44: 1103-1110, 2004.
7. Liu X, Chen H, Zhan B, Xing B, Zhou J, Zhu H and Chen Z: Attenuation of reperfusion injury by renal ischemic preconditioning: The role of NO. Biochem Biophys Res Comm 359: 526-531, 2007.
8. Hasdai D, Kornowski R and Battler A: Endothelin and myocardial ischemia. Cardiovasc Drugs Ther 8: 589-599, 1994.
9. Lang SC, Elsasser A, Scheler C, Vetter S, Tiefenbacher CP, Kühler W, Katus HA and Vogt AM: Myocardial preconditioning and remote renal preconditioning: identifying a protective factor using proteomic methods? Basic Res Cardiol 109: 149-158, 2006.
10. Zhou W, Zeng D, Chen R, Liu J, Yang G, Liu P and Zhou X: Limb ischemic preconditioning reduces heart and lung injury after an open heart operation in infants. Pediatr Cardiol 31: 22-29, 2010.
11. Tuttolomondo A, Pecoraro R, Casuccio A, Di Raimondo D, Buttà C, Clemente G, Della V, Guggino G, Arnao V, Maida C, et al: Peripheral frequency of CD4+CD28- cells in acute ischemic stroke: Relationship with stroke subtype and severity markers. Medicine (Baltimore) 94: e813, 2015.
12. Tuttolomondo A, Pedone C, Pinto A, Di Raimondo D, Fernandez P, Di Sciacca R and Licata G: Gruppo Italiano di Farmacopediometria dell`Anziano (GIFA) researchers: Predictors of outcome in acute ischemic cerebrovascular syndromes: The GIFA study. Int J Cardiol 125: 391-396, 2008.
13. Di Raimondo D, Tuttolomondo A, Butta C, Micieli S, Licata G and Pinto A: Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. Curr Pharm Des 18: 4385-4413, 2012.
14. Przepiorka-Bzdjak H, Fischer K and Brzosko M: Serum interleukin-18, Fetuin-A, soluble intercellular adhesion molecule-1, and endothelin-1 in ankylosing spondylitis, psoriatic arthritis and SAPHO syndrome. Int J Mol Sci 17: pii: E1255, 2016.
15. Dröge W: Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002.
16. Lønborg J, Kelbaek H, Vejstrup N, Jørgensen E, Helqvist S, Saunamäki K, Clemmensen P, Holmvang L, Treiman M, Jensen JS and Engstroem T: Cardioprotective effects of ischaemic preconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Cire Cardiovasc Interv 3: 34-41, 2010.
17. Hashmi MA, Ahsan B, Shah SIA and Khan MIU: Antioxidant capacity and lipid peroxidation product in pulmonary tuberculosis. Al Ame in J Med Sci 5: 313-319, 2012.
18. Muchitschegel JD, Perry TE, Liu KY, Nascimento L, Foo AA, Collard CD, Avery EG, Aranki SF, D’Ambra MN, Shernak SN, et al: Troponin is superior to electrocardiogram and creatinine kinase MB for predicting clinically significant myocardial injury after coronary artery bypass grafting. Eur Heart J 30: 1574-1583, 2009.
19. Erdil N, Ergolu T, Akca B, Disli OM, Yetkin O, Colak MC, Erdil F and Battaloglu B: The effects of N-acetylcysteine on pulmonary functions in patients undergoing on-pump coronary artery surgery: A double blind placebo controlled study. Eur Rev Med Pharmacol Sci 20: 180-187, 2016.
20. Bonservice WG, Koike MK, Saurin R, Felix GA, da Silva SM, Montero EF and Taha MO: Ischemic preconditioning and atenolol on lung injury after intestinal ischemia and reperfusion in rats. Transplant Proc 46: 1862-1866, 2014.
21. Przyklenk K, Bauer B, Ovize M, Kløra RA and Whittaker P: Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 87: 893-899, 1993.
22. Hausenloy DJ and Yellon DM: Remote ischaemic preconditioning: Underlying mechanisms and clinical application. Cardiovasc Res 79: 375–396, 2008.
23. Sivaraman V, Pickard JM and Hausenloy DJ: Remote ischaemic conditioning: Cardioprotection from afar. Anaesthesia 70: 732-748, 2015.
24. Heusch G, Botker HE, Przyklenk K, Redington A and Yellon D: Remote ischemic conditioning. J Am Coll Cardiol 65: 177-195, 2015.
25. Young PJ, Dalley P, Garden A, Horrocks C, La Flamme A, Mahon B, Miller J, Pilcher J, Weatherall M, Williams J, et al: A pilot study investigating the effects of remote ischemic preconditioning in high-risk cardiac surgery using a randomised controlled double-blind protocol. Basic Res Cardiol 107: 256, 2012.
26. Rahman IA, Mascaro JG, Steeds RP, Frenneaux MP, Nightingale P, Gosling P, Townsend P, Townsend JN, Green D and Bonser RS: Remote ischemic preconditioning in human coronary artery bypass surgery: From promise to disappointment? Circulation 122: 9266-7, 2010.
27. Venugopal V, Hausenloy DJ, Ludman A, Di Salvo C, Kolvekar S, Yap J, Lawrence D, Bognolo J and Yellon DM: Remote ischemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: A randomised controlled trial. Heart 95: 1567-1571, 2009.
28. Hausenloy DJ, Mwamarih J, Di Fabio R, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, et al: Effect of remote ischemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: A randomised controlled trial. Lancet 370: 575-579, 2007.
29. Ali N, Rizwi F, Iqbal A and Rashid A: Induced remote ischemic preconditioning on ischemia-reperfusion injury in patients undergoing coronary artery bypass surgery. J Coll Physicians Surg Pak 20: 427-431, 2010.
30. Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhausser M, Peters J, Jakob H and Heusch G: Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol 105: 657-664, 2010.
31. Hoole SP, Heck PM, Sharples L, Khan SN, Duehmke R, Densme CG, Clarke SC, Shapiro LM, Schofield PM, O’Sullivan M and Dutka DP: Cardiac remote ischemic preconditioning in coronary artery stenting (CRISP Stent) study: A prospective, randomized control trial. Circulation 119: 820-827, 2009.
32. Candilio L, Malik A, Ariti C, Barnard M, Di Salvo C, Lawrence D, Hayward M, Yap J, Roberts N, Sheikh A, Candilio L, Malik A, Ariti C, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, et al: Effect of remote ischemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: A randomised controlled trial. Lancet 370: e813, 2015.
34. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A and Spragg R: The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes and clinical trial coordination. Am J Respir Crit Care Med 149: 818-824, 1994.

35. Zhang C, Gong W, Liu H, Guo Z and Ge S: Inhibition of matrix metalloproteinase-9 with low-dose doxycycline reduces acute lung injury induced by cardiopulmonary bypass. Int J Clin Exp Med 7: 4975-4982, 2014.

36. Pilcher JM, Young P, Weatherall M, Rahman I, Bonser RS and Beasley RW: A systematic review and meta-analysis of the cardioprotective effects of remote ischaemic preconditioning in open cardiac surgery. J R Soc Med 105: 436-445, 2012.

37. Karuppasamy P, Chaubey S, Dew T, Musto R, Sherwood R, Desai J, John L, Shah AM, Marber MS and Kunst G: Remote intermittent ischemia before coronary artery bypass graft surgery: A strategy to reduce injury and inflammation? Basic Res Cardiol 106: 511-519, 2011.

38. Adabag AS, Wassif HS, Rice K, Mithani S, Johnson D, Bonawitz-Conlin J, Ward HB, McFalls EO, Kuskowski MA and Kelly RF: Preoperative pulmonary function and mortality after cardiac surgery. Am Heart J 159: 691-697, 2010.

39. Mazzeffi M, Kassa W, Gammie J, Tanaka K, Roman P, Zhan M, Griffith B and Rock P: Preoperative aspirin use and lung injury after aortic valve replacement surgery: A retrospective cohort study. Anesth Analg 121: 271-277, 2015.

40. Zimmerman RF, Ezeanuna PU, Kane JC, Cleland CD, Kempananjappa TJ, Lucas FL and Kramer RS: Ischemic preconditioning at a remote site prevents acute kidney injury in patients following cardiac surgery. Kidney Int 80: 861-867, 2011.

41. Karu I, Tahepold P, Ruusalepp A, Reimann E, Koks S and Starkopf J: Exposure to sixty min of hyperoxia upregulates myocardial humanins in patients with coronary artery disease-a pilot study. J Physiol Pharmacol 66: 899-906, 2015.

42. Pinheiro DF, Fontes B, Shimazaki JK, Heimbecker AM, Jacysyn Jde F, Rasslan S, Montero EF and Utiyama EM: Ischemic preconditioning modifies mortality and inflammatory response. Acta Cir Bras 31: 1-7, 2016.

43. Ucar G, Topaloglu E, Kandili HB and Gümüsel B: Effect of ischemic preconditioning on reactive oxygen species-mediated ischemia-reperfusion injury in the isolated perfused rat lung. Clin Biochem 38: 681-684, 2005.

44. Imai Y, Kubo K, Neely GG, Yaghubian-Malhami R, Perkman T, van Loo G, Ermolaeva M, Veldhuizen R, Leung YH, Wang H, et al: Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133: 235-249, 2008.

45. Victorino GP, Wisner DH and Tucker VL: Basal release of nitric oxide and its interaction with endothelin-1 on single vessel hydraulic permeability. J Trauma 50: 535-539, 2001.